Exact Therapeutics AS - Asset Resilience Ratio

Latest as of December 2024: 64.97%

Exact Therapeutics AS (EXTX) has an Asset Resilience Ratio of 64.97% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Exact Therapeutics AS (EXTX) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

Nkr99.54 Million
≈ $10.47 Million USD Cash + Short-term Investments

Total Assets

Nkr153.20 Million
≈ $16.12 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Exact Therapeutics AS's Asset Resilience Ratio has changed over time. See Exact Therapeutics AS book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Exact Therapeutics AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Exact Therapeutics AS market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr99.54 Million 64.97%
Short-term Investments Nkr0.00 0%
Total Liquid Assets Nkr99.54 Million 64.97%

Asset Resilience Insights

  • Very High Liquidity: Exact Therapeutics AS maintains exceptional liquid asset reserves at 64.97% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Exact Therapeutics AS Industry Peers by Asset Resilience Ratio

Compare Exact Therapeutics AS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Exact Therapeutics AS (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Exact Therapeutics AS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 64.97% Nkr99.54 Million
≈ $10.47 Million
Nkr153.20 Million
≈ $16.12 Million
-10.75pp
2023-12-31 75.72% Nkr46.43 Million
≈ $4.89 Million
Nkr61.32 Million
≈ $6.45 Million
-8.38pp
2022-12-31 84.10% Nkr69.39 Million
≈ $7.30 Million
Nkr82.51 Million
≈ $8.68 Million
-4.05pp
2021-12-31 88.15% Nkr103.69 Million
≈ $10.91 Million
Nkr117.63 Million
≈ $12.38 Million
-5.50pp
2020-12-31 93.65% Nkr159.42 Million
≈ $16.78 Million
Nkr170.23 Million
≈ $17.91 Million
+7.22pp
2019-12-31 86.43% Nkr45.03 Million
≈ $4.74 Million
Nkr52.10 Million
≈ $5.48 Million
-6.35pp
2018-12-31 92.78% Nkr58.67 Million
≈ $6.17 Million
Nkr63.23 Million
≈ $6.65 Million
+17.12pp
2017-12-31 75.66% Nkr15.15 Million
≈ $1.59 Million
Nkr20.02 Million
≈ $2.11 Million
--
pp = percentage points

About Exact Therapeutics AS

OL:EXTX Norway Biotechnology
Market Cap
$9.59 Million
Nkr91.10 Million NOK
Market Cap Rank
#26971 Global
#252 in Norway
Share Price
Nkr1.44
Change (1 day)
-1.37%
52-Week Range
Nkr1.27 - Nkr3.10
All Time High
Nkr40.90
About

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more